Format

Send to

Choose Destination
Head Neck. 2019 Aug;41(8):2636-2646. doi: 10.1002/hed.25740. Epub 2019 Mar 21.

Tumor immune microenvironment characteristics of papillary thyroid carcinoma are associated with histopathological aggressiveness and BRAF mutation status.

Author information

1
Department of Cell, Developmental & Cancer Biology, Oregon Health and Science University, Portland, Oregon.
2
Department of Otolaryngology-Head and Neck Surgery, Oregon Health and Science University, Portland, Oregon.
3
Department of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon.
4
Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon.
5
Operative Care Division, Portland Veterans' Affairs Health Care System, Portland, Oregon.
6
Department of Pathology, Oregon Health and Science University, Portland, Oregon.
7
Department of Otolaryngology-Head and Neck Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Abstract

BACKGROUND:

Papillary thyroid carcinoma (PTC) follows an indolent course; however, up to 30% of patients develop recurrent disease requiring further treatment. Profiling PTC immune complexity may provide new biomarkers for improved risk prediction.

METHODS:

Immune complexity profiles were quantitatively evaluated by multiplex immunohistochemistry (mIHC) in archived tissue sections from 39 patients with PTC, and were assessed for correlations with aggressive histopathological features based on the presence of lymphovascular invasion and/or extrathyroidal extension, and BRAF V600E mutational status.

RESULTS:

mIHC revealed two distinct immune clusters stratifying patients: a lymphoid-inflamed group (higher CD8+ T cells, reduced dendritic and mast cells) and a myeloid/hypo-inflamed group that correlated with aggressive pathological features. BRAF mutation was not associated with aggressive pathological features but did correlate with increased mast cell density.

CONCLUSIONS:

Distinct immune microenvironments exist in PTC correlating with pathological aggressiveness. Immune-based biomarkers associated with possible tumor-immune interactions may be used for risk stratification.

KEYWORDS:

biomarker; immune cell; multiplex immunohistochemistry; thyroid cancer; tumor microenvironment

PMID:
30896061
DOI:
10.1002/hed.25740

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center